Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Go back to Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.30 +0.24 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.06 | 52 Week High | $77.12 | |||
| Open | $63.09 | 52 Week Low | $49.03 | |||
| Day High | $63.40 | P/E | 41.10 | |||
| Day Low | $62.70 | EPS | $1.54 | |||
| Volume | 1,266,882 | |||||
